All In Biotech

Drug Trial Radar · NCT07405177

A Study of MK-7240 in Healthy Participants (MK-7240-009)

A Randomized, Open-label, Parallel-group Study to Assess the Pharmacokinetic Bioequivalence of Subcutaneously-administered Tulisokibart Delivered by 2 Different Autoinjectors in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

330

Actual

Start

Mar 5, 2026

Primary completion

Sep 19, 2026

Study completion Oct 12, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this study is to learn what happens to MK-7240 in a healthy person's body over time (pharmacokinetic or PK study). Researchers also want to learn about the safety of MK-7240 and if people tolerate it.

Conditions

  • Healthy

Interventions

  • Tulisokibart Form 1Biological

    Solution for injection.

  • Tulisokibart Form 2Biological

    Solution for injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of TulisokibartTime frame: At designated timepoints up to 14 weeks
  2. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of TulisokibartTime frame: At designated timepoints up to 14 weeks
  3. Maximum Plasma Concentration (Cmax) of TulisokibartTime frame: At designated timepoints up to 14 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network ( Site 0002)

    Brisbane, Queensland, Australia

  • Nucleus Network ( Site 0001)

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.